Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 plus adagrasib in KRASG12C-mutated advanced solid tumors
2023-503223-26-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of incb099280 and adagrasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Incyte. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Mar 2024; status: completed.
02
Drugs
incb099280adagrasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503223-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503223-26-00.